Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial

Journal:

The Lancet

Published:

2025-11-21

DOI:

10.1016/s0140-6736(25)02165-8

Affiliations:

8

Authors:

14

Go to article

Institutions	Authors	Share
Lilly, United States of America (USA)	6.125000	0.44
Korea University College of Medicine, South Korea	1.125000	0.08
The First Medical Center, PLAGH, China	1.125000	0.08
Centro Paulista de Investigação Clínica (CEPIC), Brazil	1.125000	0.08
University Medical Center Hamburg-Eppendorf (UKE), UHH, Germany	1.125000	0.08
The University of Texas Health Science Center at Houston (UTHealth), United States of America (USA)	1.125000	0.08
Pennington Biomedical Research Center (PBRC), LSU, United States of America (USA)	1.125000	0.08
Swansea University, United Kingdom (UK)	1.125000	0.08

Interested in Nutrition and Dietetics?